{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:25:23Z","timestamp":1785270323110,"version":"3.55.0"},"reference-count":27,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,5,25]]},"DOI":"10.1253\/circj.cj-19-0358","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T22:04:36Z","timestamp":1586556276000},"page":"994-1003","source":"Crossref","is-referenced-by-count":7,"title":["Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia\u3000\u2015 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study \u2015"],"prefix":"10.1253","volume":"84","author":[{"given":"Koutaro","family":"Yokote","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine"},{"name":"Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Niwa","sequence":"additional","affiliation":[{"name":"Niwa Family Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Hakoda","sequence":"additional","affiliation":[{"name":"Nippon Kokan Fukuyama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiki","family":"Oh","sequence":"additional","affiliation":[{"name":"Shindenhigashi Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kajimoto","sequence":"additional","affiliation":[{"name":"Senrichuo Ekimae Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukui","sequence":"additional","affiliation":[{"name":"Olive Takamatsu Medical Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyosung","family":"Kim","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Noda","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Lundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Global Medicine Development, AstraZeneca Gothenburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Yajima","sequence":"additional","affiliation":[{"name":"Research & Development, AstraZeneca K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan \u2013 2012 version. <i>J Atheroscler Thromb<\/i> 2013; 20: 517\u2013523.","DOI":"10.5551\/jat.15792"},{"key":"2","unstructured":"2. Goncalves Bos AJ, Braga Jorge L, Hirtz do Nascimento Navarro J, Farias Gerlack L, de Paula Rocha J, Guimaraes Oliveira G, et al. Comparing the prevalence and drug treatment rates of diabetes, hypertension and dyslipidemia between Japan and Brazil, using 2013 national health surveys. <i>J Clin Diabetes Pract<\/i> 2015; 1: 130."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. National Cholesterol Education Program (U.S.). Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report, National Institutes of Health, National Heart, Lung, and Blood Institute, Washington, DC, 2002.","DOI":"10.1001\/jama.285.19.2486"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arai H, Ishibashi S, Bujo H, Hayashi T, Yokoyama S, Oikawa S, et al. Management of type IIb dyslipidemia. <i>J Atheroscler Thromb<\/i> 2012; 19: 105\u2013114.","DOI":"10.5551\/jat.10447"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hirasada K, Niimura H, Kubozono T, Nakamura A, Tatebo M, Ogawa S, et al. Values of cardioankle vascular index (CAVI) between Amami islands and Kagoshima mainland among health checkup examinees. <i>J Atheroscler Thromb<\/i> 2012; 19: 69\u201380.","DOI":"10.5551\/jat.6627"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: Implications for the pathophysiology of atherosclerosis. <i>J Atheroscler Thromb<\/i> 2013; 20: 123\u2013133.","DOI":"10.5551\/jat.12849"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Han SH, Nicholls SJ, Sakuma I, Zhao D, Koh KK. Hypertriglyceridemia and cardiovascular diseases: Revisited. <i>Korean Circ J<\/i> 2016; 46: 135\u2013144.","DOI":"10.4070\/kcj.2016.46.2.135"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guyton JR, Bays HE. Safety considerations with niacin therapy. <i>Am J Cardiol<\/i> 2007; 99: 22c\u201331c.","DOI":"10.1016\/j.amjcard.2006.11.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. <i>Am J Cardiol<\/i> 2007; 99: 3c\u201318c.","DOI":"10.1016\/j.amjcard.2006.11.016"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. <i>Lipids Health Dis<\/i> 2016; 15: 118.","DOI":"10.1186\/s12944-016-0286-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. <i>J Clin Lipidol<\/i> 2014; 8: 94\u2013106.","DOI":"10.1016\/j.jacl.2013.10.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). <i>Clin Ther<\/i> 2013; 35: 1400\u20131411.","DOI":"10.1016\/j.clinthera.2013.07.420"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. <i>J Am Coll Cardiol<\/i> 2015; 65: 2267\u20132275.","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. <i>Am J Epidemiol<\/i> 2001; 153: 490\u2013499.","DOI":"10.1093\/aje\/153.5.490"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, K\u00f6nig IR, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. <i>N Engl J Med<\/i> 2016; 374: 1134\u20131144.","DOI":"10.1056\/NEJMoa1507652"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. <i>Lancet<\/i> 2007; 369: 1090\u20131098.","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, D\u00edaz R, Dyal L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>N Engl J Med<\/i> 2012; 367: 309\u2013318.","DOI":"10.1056\/NEJMoa1203859"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. <i>N Engl J Med<\/i> 2019; 380: 11\u201322.","DOI":"10.1056\/NEJMoa1812792"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Scott R, O\u2019Brien R, Fulcher G, Pardy C, D\u2019Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Diabetes Care<\/i> 2009; 32: 493\u2013498.","DOI":"10.2337\/dc08-1543"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. <i>Lancet<\/i> 2005; 366: 1849\u20131861.","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: Implications for treatment of dyslipidemia in Type 2 diabetes mellitus. <i>Clin Lipidol<\/i> 2011; 6: 9\u201320.","DOI":"10.2217\/clp.10.84"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. <i>Circulation<\/i> 2000; 102: 21\u201327.","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. <i>Circ Res<\/i> 2014; 114: 1022\u20131036.","DOI":"10.1161\/CIRCRESAHA.114.301621"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med<\/i> 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study. <i>J Clin Lipidol<\/i> 2013; 7: 199\u2013207.","DOI":"10.1016\/j.jacl.2013.01.006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: The ECLIPSE II study. <i>Vasc Health Risk Manag<\/i> 2013; 9: 563\u2013573.","DOI":"10.2147\/VHRM.S50464"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Offman E, Davidson M, Abu-Rashid M, Chai P, Nilsson C. Systemic bioavailability and dose proportionality of omega-3 administered in free fatty acid form compared with ethyl ester form: Results of a Phase 1 study in healthy volunteers. <i>Eur J Drug Metab Pharmacokinet<\/i> 2017; 42: 815\u2013825.","DOI":"10.1007\/s13318-016-0398-2"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/6\/84_CJ-19-0358\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T03:22:21Z","timestamp":1590808941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/6\/84_CJ-19-0358\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0358","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]}}}